These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6816110)

  • 41. Epidemiological markers for Pseudomonas aeruginosa. 6. Relationship between concomitant non-mucoid and mucoid strains from the respiratory tract in cystic fibrosis.
    Bergan T; Hoiby N
    Acta Pathol Microbiol Scand Suppl; 1975 Dec; 83(6):553-60. PubMed ID: 812335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.
    Chotirmall SH; Smith SG; Gunaratnam C; Cosgrove S; Dimitrov BD; O'Neill SJ; Harvey BJ; Greene CM; McElvaney NG
    N Engl J Med; 2012 May; 366(21):1978-86. PubMed ID: 22607135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis.
    De Soyza A; Perry A; Hall AJ; Sunny SS; Walton KE; Mustafa N; Turton J; Kenna DT; Winstanley C
    Eur Respir J; 2014 Mar; 43(3):900-3. PubMed ID: 24176999
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR; Pressler T; Koch C; Høiby N
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis.
    Kolpen M; Hansen CR; Bjarnsholt T; Moser C; Christensen LD; van Gennip M; Ciofu O; Mandsberg L; Kharazmi A; Döring G; Givskov M; Høiby N; Jensen PØ
    Thorax; 2010 Jan; 65(1):57-62. PubMed ID: 19846469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Bacteriological characteristics of chronic bronchial infections].
    May JR
    Poumon Coeur; 1973; 29(4):425-8. PubMed ID: 4211172
    [No Abstract]   [Full Text] [Related]  

  • 47. Circulating immune complexes, antibodies to Pseudomonas aeruginosa, and pulmonary status in cystic fibrosis.
    Lagacé J; Mercier J; Fréchette M; Fournier D; Dubreuil M; Lamarre A; Lapointe JR; Montplaisir S
    J Clin Lab Immunol; 1989 Sep; 30(1):7-11. PubMed ID: 2534928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Association between chronic colonization or infection with Pseudomonas aeruginosa and bronchial hyperreactivity in patients with cystic fibrosis].
    Valverde-Molina J; Sánchez-Solís M; Pastor-Vivero MD; García-Marcos L
    Arch Bronconeumol; 2008 Apr; 44(4):180-4. PubMed ID: 18423178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic.
    Griffiths AL; Wurzel DF; Robinson PJ; Carzino R; Massie J
    J Cyst Fibros; 2012 Jan; 11(1):49-52. PubMed ID: 21907639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis.
    Evans TJ
    Future Microbiol; 2015; 10(2):231-9. PubMed ID: 25689535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis.
    Hla SW; Hui KP; Tan WC; Ho B
    J Clin Microbiol; 1996 Mar; 34(3):575-8. PubMed ID: 8904417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polyagglutinable Pseudomonas aeruginosa from cystic fibrosis patients. A survey.
    Ojeniyi B
    APMIS Suppl; 1994; 46():1-44. PubMed ID: 7811529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Analysis of the frequency of isolation and drug resistance of microorganisms isolated from the airways of adult CF patients treated in the Institute of Tuberculosis and Lung Disease during 2008-2011].
    Iwańska A; Nowak J; Skorupa W; Augustynowicz-Kopeć E
    Pneumonol Alergol Pol; 2013; 81(2):105-13. PubMed ID: 23420426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces.
    Panagea S; Winstanley C; Walshaw MJ; Ledson MJ; Hart CA
    J Hosp Infect; 2005 Feb; 59(2):102-7. PubMed ID: 15620443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis.
    Duff RM; Simmonds NJ; Davies JC; Wilson R; Alton EW; Pantelidis P; Cox MJ; Cookson WO; Bilton D; Moffatt MF
    Eur Respir J; 2013 Apr; 41(4):991-3. PubMed ID: 23543647
    [No Abstract]   [Full Text] [Related]  

  • 56. Newly diagnosed cystic fibrosis in middle and later life.
    Hunt B; Geddes DM
    Thorax; 1985 Jan; 40(1):23-6. PubMed ID: 3918355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenotypic differences among clinically isolated mucoid Pseudomonas aeruginosa strains.
    Pugashetti BK; Metzger HM; Vadas L; Feingold DS
    J Clin Microbiol; 1982 Oct; 16(4):686-91. PubMed ID: 6818245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucoid gram-negative bacilli in cystic fibrosis.
    Kelly NM; Falkiner FR; Keane CT; Fitzgerald MX; Tempany E
    Lancet; 1983 Mar; 1(8326 Pt 1):705. PubMed ID: 6132059
    [No Abstract]   [Full Text] [Related]  

  • 59. Mucoid Pseudomonas aeruginosa in cystic fibrosis.
    Henry RL; Dorman DC; Brown J; Mellis C
    Aust Paediatr J; 1982 Mar; 18(1):43-5. PubMed ID: 6808983
    [No Abstract]   [Full Text] [Related]  

  • 60. Pseudomonas aeruginosa is retained in the bronchi of cystic fibrotics by the increased transepithelial potential.
    Dealler SF; Holton A
    Med Hypotheses; 1992 Mar; 37(3):186-90. PubMed ID: 1584109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.